<DOC>
	<DOCNO>NCT00950456</DOCNO>
	<brief_summary>The purpose observational study , initiate soon licensed H1N1 Pandemic Influenza Vaccine use mass vaccination campaign , estimate incidence medically-attended adverse event vaccinated subject .</brief_summary>
	<brief_title>Observational Study Assess Safety H1N1 Pandemic Influenza Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female subject , per indication license per official vaccine recommendation , eligible participation study : They administer CELVAPAN ( = BaxterÂ´s H1N1 pandemic influenza vaccine ) They 2 month age old time first vaccine administration Their medical history available The investigator believe comply foreseen vaccination schedule reliably observe sign symptom adverse event observational period They and/or parent ( ) /legal guardian ( ) provide write informed consent , assent appropriate , prior study entry accord national law Male female subject exclude participation study : They already administer another H1N1 pandemic vaccine They contraindication vaccination ( per Summary Product Characteristics and/or relevant national immunization guideline )</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>